The 2023 ASA guidance proposed stopping GLP-1 RAs for one half-life without modifying the standard preoperative fasting time as a measure to mitigate the aspiration risk
Overview GLP-1 receptor agonists are reshaping how we approach Type 2 diabetes and obesity, offering hope to millions worldwide
These medications arent always accessible to people who may benefit from them: They are expensive (hundreds of dollars each month) and not always covered by insurance
Even with all my nutrition training and the science in front of me, I didnt jump in right away
Graham, A., Livingston, G., Purnell, L
ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article